Condition: Coronavirus Disease (COVID-19)

The primary objectives of this phase 3, multicenter, randomized, double-blind, placebo-controlled study are to determine the efficacy, safety, and tolerability of molnupiravir (MK-4482) compared with placebo for the prevention of laboratory-confirmed coronavirus disease 2019 (COVID-19) through Day 14 in participants with undetectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in baseline nasopharyngeal (NP) swabs.